Effect of tumour necrosis factor on the uptake of specific and control monoclonal antibodies in a human tumour xenograft model
Open Access
- 1 April 1995
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 71 (4) , 660-665
- https://doi.org/10.1038/bjc.1995.131
Abstract
The investigations reported in this paper aim to exploit tumour necrosis factor (TNF)-induced vascular changes in an attempt to increase the tumour uptake of specific monoclonal antibody. The vascular permeability to monoclonal antibody of a human tumour xenograft increased 2.6-fold by 1 h post injection of 2.5 x 10(3) U of TNF, although this effect was lost by 3 h. The normal tissues also demonstrated increased vascular permeability to IgG, but to a lesser extent. Liver permeability increased 1.5-fold at 1 h but returned to the control value by 6 h. Lung permeability increased 1.4-fold at 1 h post injection and returned to normal by 3 h. Muscle values were not significantly increased compared with controls. The blood activity was cleared more quickly in the TNF-treated mice (t1/2 beta = 101 h, compared with 121 h in control mice). This was probably due to the increased vascular permeability in normal organs of treated mice. At 1 day and 3 days post injection, the tumour uptake of the specific, but not the control, antibody was significantly increased by 25% and 29% respectively. This resulted in an increase in the area under the tumour activity curve, and therefore tumour radiation dose, of 25% in treated compared with control mice. In addition, a consequence of the faster blood clearance of the isotope in the TNF-treated mice was a reduction in the area under the blood activity curve of 12%, thereby reducing systemic toxicity. The increase in vascular permeability to IgG following TNF injection resulted in both specific and control antibodies having improved access to the tumour antigens, and a transient increase in uptake was observed. Only in the case of the specific antibody was the increase maintained, since this antibody binds to the available antigenic sites, whereas the control antibody was cleared from the tumour without binding. No evidence of tumour necrosis was observed at the TNF doses given, nor was there any toxicity to the mice.Keywords
This publication has 45 references indexed in Scilit:
- Tumour necrosis factor increases tumour uptake of Co-administered antibody-carboxypeptidase G2 conjugateEuropean Journal Of Cancer, 1993
- Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid moleculeBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1991
- Role of cytokines (interleukin 1, tumor necrosis factor, and transforming growth factor beta) in natural and lipopolysaccharide-enhanced radioresistance.The Journal of Experimental Medicine, 1991
- Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A sarcoma, and relation to curative activityThe Journal of Pathology, 1989
- Increased Vascular Permeability in Organs Mediated by the Systemic Administration of Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 in MiceJNCI Journal of the National Cancer Institute, 1988
- Another chapter in the long history of endotoxinNature, 1987
- Vascular volume and permeability of human and murine tumors grown in athymic miceCancer Letters, 1985
- Cloning and expression in Escherichia coli of the gene for human tumour necrosis factorNature, 1985
- Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycolurilBiochemical and Biophysical Research Communications, 1978
- CONTRIBUTION TO THE KNOWLEDGE OF SARCOMAAnnals of Surgery, 1891